COMP <GO>
RTX vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
RTX Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RTX 8
— TMO 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $199.80 (+0.20%) • MKT CAP: $269.08B
roic
7.20%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RTX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RTX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 7.20% | 9.30% | -2.10 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.5x | 30.4x | -3.90 | RTX | /valuation <GO> |
| Free Cash Flow Yield | 2.95% | 2.40% | +0.55 | RTX | /fcf-yield <GO> |
| Operating Margin | 10.50% | 17.40% | -6.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.60% | 15.10% | -7.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 9.70% | 3.90% | +5.80 | RTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.33% | 0.24% | +1.09 | RTX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.73 | 4.50 | -1.77 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | RTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.70% | -0.10 | RTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.8 | 59.1 | +1.62 | RTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.92 | 0.94 | -0.02 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.2x | 36.3x | +0.90 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $269.08B | $262.22B | $6.86B | RTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RTX REV | TMO REV | RTX GROSS % | TMO GROSS % | RTX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.60B | $44.56B | 44.0% | 44.0% | $7.94B | $6.29B |
| FY 2024 | $80.74B | $42.88B | 44.0% | 44.0% | $4.53B | $7.27B |
| FY 2023 | $68.92B | $42.86B | 44.0% | 44.0% | $4.78B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RTX // BETA 0.92
TMO // BETA 0.94